# 2026-12959: Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

2026-12959, Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-26, effective 2026-06-26; PRIA reads it as touching household money (as of 2026-07-03).

- Canonical: https://policyrisk.com/federal-register/2026-12959
- As of: 2026-07-03
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12959
- Title: Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 38718
- Published: 2026-06-26
- Effective: 2026-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-03

## Summary

The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that prednisolone tablet, 5 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generics Stay Available for Prednisolone 5 mg: benefit, low. The FDA has determined that prednisolone tablet, 5 mg, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, patients and pharmacies can expect continued access to affordable generic versions without interruptions or extra costs, and ANDAs that refer to…
- ANDA Approvals for Prednisolone 5 mg Allowed: benefit, medium. The FDA will not begin procedures to withdraw approval of approved abbreviated new drug applications (ANDAs) that refer to prednisolone tablet, 5 mg, and may continue to approve additional ANDAs that reference this product if they meet legal and regulatory requirements. The product remains listed i…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-12959 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/26/2026-12959/determination-that-prednisolone-tablet-5-milligrams-was-not-withdrawn-from-sale-for-reasons-of)
- [2026-12959 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12959.pdf)

## Related
- [Previous: 2026-12958, Agency Forms Undergoing Paperwork Reduction Act Review](https://policyrisk.com/federal-register/2026-12958)
- [Next: 2026-12960, Silicon Metal From Republic of Kazakhstan: Final Results of the Expedited First…](https://policyrisk.com/federal-register/2026-12960)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12959 (as of 2026-07-03).
